Sherman L. Matthew's most recent trade in Deciphera Pharmaceuticals Inc was a trade of 69,100 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Feb. 15, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Deciphera Pharmaceuticals Inc | Matthew L. Sherman | EVP & Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 69,100 | 69,100 | - | - | Stock Option (Right to Buy) | |
| Deciphera Pharmaceuticals Inc | Sherman L. Matthew | EVP & Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 17,275 | 111,354 (0%) | 0% | 0 | Common Stock | |
| Deciphera Pharmaceuticals Inc | L. Sherman Matthew | EVP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 15.62 per share. | 15 Feb 2024 | 2,615 | 108,739 (0%) | 0% | 15.6 | 40,840 | Common Stock |
| Deciphera Pharmaceuticals Inc | L. Matthew Sherman | EVP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 14.47 per share. | 16 Jan 2024 | 2,435 | 94,079 (0%) | 0% | 14.5 | 35,234 | Common Stock |
| Deciphera Pharmaceuticals Inc | Matthew Sherman L. | EVP & Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Dec 2023 | 8,244 | 99,306 (0%) | 0% | - | Common Stock | |
| Deciphera Pharmaceuticals Inc | Matthew L. Sherman | EVP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 15.37 per share. | 12 Dec 2023 | 2,792 | 96,514 (0%) | 0% | 15.4 | 42,905 | Common Stock |
| Deciphera Pharmaceuticals Inc | Matthew L. Sherman | EVP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 14.40 per share. | 16 Jun 2023 | 1,655 | 87,686 (0%) | 0% | 14.4 | 23,835 | Common Stock |
| Deciphera Pharmaceuticals Inc | Matthew L. Sherman | EVP & Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2023 | 65,900 | 65,900 | - | - | Stock Option (Right to Buy) | |
| Deciphera Pharmaceuticals Inc | Matthew L. Sherman | EVP & Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2023 | 16,488 | 89,116 (0%) | 0% | 0 | Common Stock | |
| Deciphera Pharmaceuticals Inc | Matthew L. Sherman | EVP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 15.10 per share. | 15 Feb 2023 | 971 | 88,145 (0%) | 0% | 15.1 | 14,661 | Common Stock |
| Deciphera Pharmaceuticals Inc | Matthew L. Sherman | EVP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 21.24 per share. | 17 Jan 2023 | 2,403 | 72,628 (0%) | 0% | 21.2 | 51,043 | Common Stock |
| Deciphera Pharmaceuticals Inc | Matthew L. Sherman | EVP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 18.73 per share. | 03 Oct 2022 | 2,587 | 74,297 (0%) | 0% | 18.7 | 48,455 | Common Stock |
| Deciphera Pharmaceuticals Inc | Matthew L. Sherman | EVP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 10.75 per share. | 16 Jun 2022 | 1,768 | 76,884 (0%) | 0% | 10.8 | 19,006 | Common Stock |
| Deciphera Pharmaceuticals Inc | Matthew L. Sherman | EVP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 9.05 per share. | 16 Feb 2022 | 984 | 76,790 (0%) | 0% | 9.0 | 8,905 | Common Stock |
| Deciphera Pharmaceuticals Inc | Matthew L. Sherman | EVP & Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2022 | 82,000 | 82,000 | - | - | Stock Option (Right to Buy) | |
| Deciphera Pharmaceuticals Inc | Matthew L. Sherman | EVP & Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2022 | 20,500 | 77,774 (0%) | 0% | 0 | Common Stock | |
| Deciphera Pharmaceuticals Inc | Matthew L. Sherman | EVP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 33.17 per share. | 04 Oct 2021 | 2,659 | 46,029 (0%) | 0% | 33.2 | 88,199 | Common Stock |
| Pieris Pharmaceuticals Inc | Matthew L. Sherman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2021 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Deciphera Pharmaceuticals Inc | Matthew L. Sherman | EVP & Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2021 | 49,900 | 49,900 | - | - | Stock Option (Right to Buy) | |
| Deciphera Pharmaceuticals Inc | Matthew L. Sherman | EVP & Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2021 | 11,100 | 48,386 (0%) | 0% | 0 | Common Stock | |
| Deciphera Pharmaceuticals Inc | Matthew L. Sherman | EVP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 48.87 per share. | 16 Feb 2021 | 132 | 37,286 (0%) | 0% | 48.9 | 6,451 | Common Stock |
| Deciphera Pharmaceuticals Inc | Matthew L. Sherman | EVP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 34.43 per share. | 09 Dec 2020 | 207 | 37,418 (0%) | 0% | 34.4 | 7,127 | Common Stock |
| Deciphera Pharmaceuticals Inc | Matthew L. Sherman | EVP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2020 | 207 | 147,096 | - | - | Stock Option (Right to buy) | |
| Deciphera Pharmaceuticals Inc | Matthew L. Sherman | EVP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Nov 2020 | 2,697 | 147,303 | - | - | Stock Option (Right to buy) | |
| Deciphera Pharmaceuticals Inc | Matthew L. Sherman | EVP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 34.43 per share. | 16 Nov 2020 | 2,697 | 37,211 (0%) | 0% | 34.4 | 92,858 | Common Stock |
| Deciphera Pharmaceuticals Inc | Matthew L. Sherman | EVP & Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 51.15 per share. | 02 Oct 2020 | 2,632 | 34,128 (0%) | 0% | 51.1 | 134,618 | Common Stock |